Early Life Development of Toxicokinetic Pathways: Framework Case Examples and Implications for Safety Assessment
|
|
- Chad Terry
- 5 years ago
- Views:
Transcription
1 Early Life Development of Toxicokinetic Pathways: Framework Case Examples and Implications for Safety Assessment Gary Ginsberg Connecticut Department of Public Health
2 Conflict of Interest Statement Some of the research presented was funded by USEPA/NCEA and USEPA/OCHP No personal or institutional COIs What is presented is my own perspective and does not represent the views or policy of the CT DPH
3 Toxicokinetics: Compare Internal Doses Across Species or People TK what the body does to the chemical vs. TD what the chemical does to the body TK kinetics (rate) of processes chemical fate Absorption how rapidly and completely absorbed across g.i. tract, skin or lungs Distribution where will chemical concentrate Central compartment vs tissues/fat Ability to cross placenta or BBB Metabolism clearance but could lead to more toxicity Excretion clearance-urine, feces, exhaled, breast milk Determine media best for biomonitoring
4 Reasons for Differing TK in Early Life Prenatal 3 forms of exposure Parent compound from maternal system Metabolites from maternal system Metabolites from fetal system Fetal CYPs different than adult CYPs (e.g., 3A7) 3-MC in C57/DBA backcrosses Greatest risk if fetus is Ahr+ and mother is AHr- Early Postnatal Rate of intake per body weight higher GI absorption may be enhanced (e.g., Pb) Distribution altered Less body fat BBB immature, more access to CNS Many CYPs immature, low expression Urinary excretion slower, less blood flow to kidney Glucuronidation immature, sulfation may predominate
5 Overview of Children s Developmental Features that can Affect TK Developmental Feature Body Composition: Lower lipid content Greater water content Relevant Age Period Birth through 3 months TK Implications Less partitioning and retention of lipid soluble chemicals; larger Vd for water soluble chemicals Larger liver wt/body wt Immature Enzyme Function Phase I reactions Phase II reactions Larger brain wt/bwt; Greater blood flow to CNS; higher BBB permeability Immature Renal Function Limited Serum Protein Binding Capacity Birth - 6 yrs but largest diffs. in 1st 2 yrs Birth -1 year but largest diffs. in first 2 months Birth - 6 yrs but largest diffs. first 2 yrs Greater opportunity for hepatic extraction and metabolic clearance; however, also greater potential for activation to toxic metabolites Slower metabolic clearance of many drugs and environmental chemicals; less metabolic activation but also less removal of activated metabolites Greater CNS exposure, particularly for water soluble chemicals which are normally impeded by BBB Birth - 2 months Slower elimination of renally cleared chemicals / metabolites Birth - 3 months Potential for greater amount of free toxicant and more extensive distribution
6 Caveat: Altered Enzymes Not Always Altered Kinetics Flow limited rather than capacity limited metabolism Overlapping enzymes Other physiological and metabolic differences that can compensate
7 PBTK Modeling Simulate ADME based upon Known physiologic constants Blood flows, organ sizes, body weight Chemical-specific properties g.i. absorption rate Partition coefficients blood:air, liver:blood, fat:blood Plasma protein binding Metabolic rate constants Urinary excretion rate Calibrate/Validate against actual data
8 Examples Where Early Life TK Matters Immature glucuronidation bilirubin high in newborns jaundice Grey baby syndrome CAP in newborns slow glucuronidation methb Immature carboxylesterases OP pesticide tox greater in juvenile rats
9 Age-Dependence of CPF Inhibition of Brain Cholinesterase in Juvenile Rats Timchalk et al. Toxicology, 2006
10 TK Features, Older Children Liver larger per body weight CYPs catch up to adult levels Increasing lipid mass per body weight
11 Physiological Database for PBPK Modeling ILSI 1994 Rats, Mice, Humans USEPA 2009 Early life through senescence Humans
12 Enzyme Ontogeny Data Liver bank studies probing mrna, protein expression and/or activity of enzymes towards their respective substrates including drug PK literature Hakkola et al Vieira et al. 1997, 1998 CYP2E1 and other CYPs Alcorn and McNamara 2002 CYP Ontogeny Ginsberg et al clearance of pharmaceuticals in vivo Ginsberg et al TAP Hines et al Johnsrud et al CYP2E1 Hines et al human liver carboxylesterases Phase II: McCarver and Hines 2002 GSH levels in plasma: Chantry et al.1999
13 Use of Pediatric Pharmacokinetic Data in Children s Risk Assessment for Environmental Agents Child Illness Drug Blood level Therapy Pharmacokinetics Ontogeny of TK Children Exposure Internal Dose Risk
14 Ginsberg et al. Tox Sci 2002
15 Ginsberg et al. Tox Sci 2002
16 Ginsberg et al. Tox Sci 2002
17 Figure 4 Analysis of Children's Pharmacokinetic Database Half-Life Results for Glucuronidation Substrates Lorazepam, Morphine, Oxazepam, Trichloroethanol, Valproic Acid, Zidovudine Children's t1/2 relative to adults *** *** ** ** ** _ 1.0 (adults) 0.00 Premature neonates Full term neonates 1 wk - 2 mo 2-6 mo 6 mo - 2 yr 2-12 yr yr * p<0.1, **p<0.05, ***p<0.01 Ginsberg et al. Tox Sci 2002
18 Individual Half-Life Data from the Children s PK Database Hattis et al. Risk Anal Log(Child/Adult T1/2) CYP 1A2 Log(Child/Adult T1/2) CYP 2C Log(Child/Adult T1/2) CYP 3A Log(Child/Adult T1/2) Glucuron Log(Child/Adult T1/2) Renal Log(Child/Adult T1/2) Child/adult = 1 Child/adult = Child = averag Age (days) Child/Adult TK Differences and Intra-Child Variability greatest in first weeks of life
19 CYP2E1 Protein Expression in Children s Age Groups as a Fraction of Adult Levels 1.20 Fraction of Adult GM Value CYP2E1 content (Vieira et al. 1996) CYP2E1 content (Johnsrud et al. 2003) hours 1-7 days 8-28 days 1-3 months 3-12 mos 1-10 years Adult
20 Ontogeny of Plasma Glutathione Chantry, et al., 1999 Mean Age (Weeks) GSH Ratio to Adult SD a to Adult
21 Ontogeny of Human Hepatic Phase I Enzymes Lines not carrying all the way to adulthood represent non-availability of data. Reprinted from (Saghir et al., 2012).
22 Toxicokinetic MOA Critical to Understanding Influence of Ontogeny Distribution: Is chemical fat seeking or highly protein bound? May be more free toxicant in young children Metabolism: Is chemical activated which enzymes? Less metabolite may be formed in early life May also be slower metabolite removal Excretion: glucuronidation and urinary excretion are subject to early life immaturities Longer half life of many pharmas in neonates
23 TK MOA and Ontogeny Considerations Parent Compound Active Early life slow clearance, ed internal dose Toluene Nong et al Toluene Internal Dose in Children (Modeled Lines) vs Adults (Data Points) After a 7 Hour Inhalation Exposure
24 MOA Ontogeny Considerations Metabolite Active Early life may be less sensitive Acetaminophen Early life may have higher internal dose E.g., OPs and deficient CE detoxification Early life may be similar to adult E.g., Acrylamide (Walker et al. 2007)
25 Walker et al. 2007
26 Acrylamide Case Study Summary Neonatal acrylamide AUC up to 3x >adult 5x > for 99 th % neonate to median adult ratio Less differential in older ages where dietary exposure is more prevalent Glycidamide AUC: children 2x> adults 5x differential for 99 th % child to adult ratio Differences quenched by immaturities going in opposite directions Dosimetry in humans greater than in rats
27 TK Intraspecies UF for HHRA Need to consider TK variability for all reasons, not just immaturity E.g., polymorphisms, other stressors/exposures 3 fold 5 fold upper % child / mean adult captures both child/adult difference and intra-child variability
28 Child/Adult Differences: Need to Consider Upper %, Not Just Mean Difference (Dorne et al. Food Chem Tox 2005)
29 Dorne and Renwick, Tox Sci 2005 In the absence of data on the activity of the relevant pathway(s) of elimination in neonates and the consequences of metabolism (i.e., detoxication or activation), an extra uncertainty factor higher than that in adults for polymorphic metabolism (CYP2D6, CYP2C19, NAT) may be an option to be considered by risk assessors and risk managers (Dorne et al., 2005).
30 Child/Adult Differences in Inhaled Particle and Gas Dosimetry Diagrammatic Representation of Three Respiratory Tract Regions, USEPA 1994
31 Regional Surface Area (cm 2 ) and Ventilation Rates in 3 Month Old Children and Adults
32 Ginsberg et al. Inhal Toxicol 2010
33 Ginsberg et al. Inhalation Toxico l 2010
34 Scoping Early Life TK Issues for HHRA Are data available to inform: Qualitative scoping assessment? Quantitative PBTK assessment? Is a model needed or can we make some judgements without PBTK? How much variability/uncertainty does early life TK add to the early life risk assessment? Relative to other factors/data gaps in the assessment Relative to standard intraspecies UF for TK (3.3 fold)
35 Framework for Scoping Early Life TK 1. What are the key determinants of chemical TK? 2. What is the ontogeny profile for these fate pathways? 3. What are implications for internal dose in early life? 4. Are there supporting in vivo data? a. TK data in children mostly available for pharmas b. TD data in children or animals 5. What is the need for and feasibility of PBTK modeling? 6. Synthesize all the relevant information: a. Qualitative evaluate early life vulnerabilities, variability, uncertainty relative to default UF b. Quantitative--prioritize the need for PBTK 1) What would be learned and what uncertainties likely to encounter?
36 Case Study Early Life TK Case Studies to Illustrate the Framework Chemicals(s) Highlighted Pathways #1 Acetaminophen UGT, SULT, GST, CYP2E1 #2 Chlorpyrifos CYPs 2C19, 2B6, 1A2, PON1 #3 Toluene CYPs 2E1, 1A2 #4 Aromatic Amines CYP1A2, NAT2 #5 Trichloroethylene CYP2E1, GST Abbreviations: UGT uridine diphosphate glucuronyl transferase; SULT ulfotransferase; GST glutathione S-transferase; CYP cytochrome P-450; PON paraoxonase; NAT n-acetyltransferase.
37 How Might Metabolic Immaturities Affect Acetaminophen Internal Dose? Immature Mature Immature Immature?
38 Implications of Acetaminophen Case Study Immaturity in activation (CYP2E1) and detoxification (glucuronidation) occur at same time No window of heightened TK vulnerability Sulfation capacity helpful with low/moderate doses GSH immaturity an uncertainty but downstream of activation step Poisoning cases suggest infants less vulnerable than older groups Penna and Buchanan 1991; Isbister et al. 2001; Porta et al PBTK modeling feasible Adult model exists, can be adapted to children s parameters
39 How might Metabolic Immaturities Affect Aromatic Amine Internal Dose? Immature Immature Immature Immature Immature Immature Immature Immature
40 Implications of Aromatic Amine Case Study Immaturity in NAT a predisposing factor Immaturity in CYP1A2 a protective factor Other CYPs can activate AAs 1B1 no ontogeny data; 2A6 rapid development Immaturity in glucuronidation a predisposing factor Maturity in sulfation could go either way In vivo data for early life-increasing DNA adducts with increasing age in mice (McQueen and Chau 2003) Synthesis: Potential exists for a TK window of vulnerability in early life due to some activation with limited detox capability PBTK potential limited by no published model for adults
41 How Might Metabolic Immaturities Affect TCE Internal Dose? CYP2E1: immature CYP2B1: mature Immature? Immature
42 Implications of Trichloroethylene Case Study Some activation in liver likely even in newborns due to CYP2B1 Deficient glucuronidation may predispose liver to TCE toxicity/cancer Kidney less likely to be vulnerable in early life Blood flow to kidney is less than in older ages Excess TCE not oxidized can be exhaled GSH immaturity would be protective Importance of PBTK Modeling High potential for greater internal dose in liver Potential for PBTK Modeling Human model could be adapted Need better definition of which CYPs in early life
43 Summary Early Life / Adult internal dose differences chemical-specific 3x TK variability factor reasonable in average case 5-10x considering intra-child variability Therefore, need to examine each case Novel pathways, increased respiratory exposure not considered in HHRA Research need: chemical metabolism in fetal and postnatal liver bank samples Scoping early life TK can help determine: Whether immaturities exist that might impact internal dose Whether PBTK modeling is warranted Whether PBTK modeling is feasible Identify critical data gaps and areas of uncertainty qualitative assessment
44 References Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet. 2002;41(12): Chantry et al. Plasma glutathione concentrations in non-infected infants born from HIV-infected mothers: developmental profile. P R Health Sci J (3): Dorne JL, Renwick AG. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol Sci Jul;86(1):20-6. Epub 2005 Mar 30. Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol Feb;43(2): Ginsberg G et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci (2): Ginsberg G et al. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol Jul 15;198(2): Hakkola et al. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol (5): Hattis D et al. Differences in pharmacokinetics between children and adults--ii. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal (1): Hines. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4): Hines RN et al. Age-Dependent Human Hepatic Carboxylesterase 1 (CES1) and Carboxylesterase 2 (CES2) Postnatal Ontogeny. Drug Metab Dispos
45 References (cont) Isbister et al. Pediatric acetaminophen overdose. J Toxicol Clin Toxicol. 2001;39(2): Johnsrud EK et al. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther. 2003;307(1):402-7 McCarver, Hines The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther (2): McQueen CA, Chau B. Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity. Toxicol Sci (2): Nong A et al. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol Appl Pharmacol Jul 1;214(1): Penna A1, Buchanan N. Paracetamol poisoning in children and hepatotoxicity. Br J Clin Pharmacol (2): Saghir SA. Ontogeny of mammalian metabolizing enzymes in humans and animals used in toxicological studies. Crit Rev Toxicol (5): Timchalk C et al. Age-dependent pharmacokinetic and pharmacodynamic response in preweanling rats following oral exposure to the organophosphorus insecticide chlorpyrifos. Toxicology. 2006; 220(1): Vieira et al. Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem (2): Walker K et al. Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences. J Toxicol Environ Health A. 2007; 70(24):
46 Acknowledgements Toxicokinetics collaborators: Bob Sonawane US EPA Brenda Foos US EPA Dale Hattis, Katie Walker Clark University
Ensuring Safety for Early Life Exposures: Adequacy of Current Methods and Opportunities to Advance the Science
Ensuring Safety for Early Life Exposures: Adequacy of Current Methods and Opportunities to Advance the Science Susan Felter, PhD Procter & Gamble Central Product Safety Felter.sp@pg.com May 20, 2016 Conflict
More informationPharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA
Pharmacogenetics of Codeine Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA 1 Codeine Overview Naturally occurring opium alkaloid Demethylated to morphine for analgesic effect
More informationPractical Application of PBPK in Neonates and Infants, Including Case Studies
Practical Application of PBPK in Neonates and Infants, Including Case Studies Presented at the conference : Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A
More informationPediatric Drug Development Current Challenges
Pediatric Drug Development Current Challenges Robert Ward, MD, FAAP, FCP Professor Emeritus, Pediatrics Founder Univ Utah Pediatric Pharmacology Program Former Attending Neonatologist University of Utah
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationChapter 4. Drug Biotransformation
Chapter 4 Drug Biotransformation Drug Biotransformation 1 Why is drug biotransformation necessary 2 The role of biotransformation in drug disposition 3 Where do drug biotransformation occur 4 The enzymes
More informationB. Incorrect! Compounds are made more polar, to increase their excretion.
Pharmacology - Problem Drill 04: Biotransformation Question No. 1 of 10 Instructions: (1) Read the problem and answer choices carefully, (2) Work the problems on paper as 1. What is biotransformation?
More informationAGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA)
HESI ILSI Health and Environmental Sciences Institute AGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA) ADME Task Force Hugh A. Barton, PhD National Center for Computational Toxicology Office of Research
More informationIncorporating Gene-Environment Information into Kinetic Models: Lessons Learned and Future Challenges
Incorporating Gene-Environment Information into Kinetic Models: Lessons Learned and Future Challenges Presenters: William C. Griffith, Jaya Ramaprasad, Elaine M. Faustman Institute for Risk Analysis and
More informationMEDCHEM 570. First Midterm. January 30, 2015
Name MEDCHEM 570 First Midterm January 30, 2015 Instructions: Exam packet totals 7 pages. The last page has a 5 points extra credit question. If you need additional space for a question go to the back
More informationENVIRONMENTAL TOXICOLOGY
ENVIRONMENTAL TOXICOLOGY Chapter 4 Toxicokinetics Mohd Amir Bin Arshad Toxicokinetics study on how a substance gets into the body and what happens to it in the body" The kinetics (movement) of substances
More informationA Regional Model of Lung Metabolism for Improving Species Dependent Descriptions of 1,3-Butadiene and its Metabolites
A Regional Model of Lung Metabolism for Improving Species Dependent Descriptions of 1,3-Butadiene and its Metabolites Harvey Clewell, Jerry Campbell, and Cynthia VanLandingham ENVIRON and The Hamner Institutes
More informationChapter 9. Biotransformation
Chapter 9 Biotransformation Biotransformation The term biotransformation is the sum of all chemical processes of the body that modify endogenous or exogenous chemicals. Focus areas of toxicokinetics: Biotransformation
More informationDrug Metabolism Phase 2 conjugation reactions. Medicinal chemistry 3 rd stage
Drug Metabolism Phase 2 conjugation reactions Medicinal chemistry 3 rd stage 1 Phase II or Conjugation reactions 1. Glucuronic acid conjugation 2. Sulfate conjugation 3. Glycine and Glutamine conjugation
More informationINTRODUCTION TO PHARMACOKINETICS
INTRODUCTION TO PHARMACOKINETICS 1 http://www.biology.iupui.edu/biocourses/biol540/4pipeline2css.html 2 PHARMACOKINETICS 1. ABSORPTION 2. DISTRIBUTION 3. METABOLISM 4. EXCRETION ALL THESE PROCESSES ARE
More informationDose response relationships: biological and modeling aspects
Dose response relationships: biological and modeling aspects Jason Aungst, Ph.D. Office of Food Additive Safety Center for Food Safety and Applied Nutrition U.S. Food and Drug Administration The findings
More informationAim of the subject I. Topics. Aim of the subject II.
Aim of the subject I. Environmental risk factors teach the basic concepts in connection with the environment (exposition epidemic, toxicology, and other factors) understand the environmental risk factors
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationCytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences
Hepatic Drug Metabolism Eva Brittebo Dept Pharmaceutical Biosciences Background Cytochrome P450 (CYP) Liver metabolism Liver toxicity Inhibition and induction Polymorphism 15-05-13 2 Plasma concentration
More informationBIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX
BIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification Luděk Bláha, PřF MU, RECETOX www.recetox.cz Metabolism and detoxification Chemicals enter body... mostly via food Pass directly
More informationDANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR
Research support by Interagency Agreement between NTP/NIEHS and NCTR/FDA The opinions presented are not necessarily those of the U.S. FDA or NTP NCTR/FDA Research on BPA: Integrating pharmacokinetics in
More informationControlling ADME through Chemical Design. Marty Mulvihill Chris Vulpe
Controlling ADME through Chemical Design Marty Mulvihill Chris Vulpe ADME Chemical Processes in ADME Wang and Skolnik, Chemistry and Biodiversity, 2009, 1887. Controlling toxicity through ADME Toward molecular
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationCurrent Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity
More informationIndustrial Toxicology
Industrial Toxicology Learning Objectives Know the assumptions of the doseresponse and time-course curves Be able to define and label key points of a curve Know the difference between potency and efficacy
More informationPharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives
PCTH 325 Pharmacokinetics Dr. Shabbits jennifer.shabbits@ubc.ca September 12, 2013 Learning Objectives 1. Interpret Concentration vs graphs and use them to calculate half life and predict drug concentration
More informationToxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine
Toxicant Disposition and Metabolism Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine chambers@cvm.msstate.edu Definitions Disposition Absorption passage across membrane.
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationADME Issues in Children: Pediatric Pharmacokinetics
ADME Issues in Children: Pediatric Pharmacokinetics John N. van den Anker, MD, PhD, FCP, FAAP Executive Director Pediatric Pharmacology Research Unit Chief, Division of Pediatric Clinical Pharmacology
More informationDISCUSSION GROUP 3. Mechanism of carcinogenicity. EFSA Scientific Colloquium on Acrylamide carcinogenicity, 22/23 May
DISCUSSION GROUP 3 Mechanism of carcinogenicity EFSA Scientific Colloquium on Acrylamide carcinogenicity, 22/23 May 2008 1 1. Review the recent evidence for the mutagenicity and genotoxicity of acrylamide
More informationEVE 491/591 Toxicology. Toxicant Entry into the Body 2/19/2018. Absorption and Fate of a Toxicant
EVE 491/591 Toxicology Lecture #7 1. Absorption of Toxicants 2. Case study Part VI Toxicant Entry into the Body Toxicants must defeat barriers to absorption The respiratory system The digestive system
More informationDEVELOPMENTAL PK/PD: WHAT HAVE WE LEARNT? Geoff Tucker
DEVELOPMENTAL PK/PD: WHAT HAVE WE LEARNT? Geoff Tucker UNDERSTANDING AND PREDICTING PK/PD IN JUVENILES PHARMACOKINETICS Can we scale from juvenile animals? Can we scale from allometry? Can we scale from
More informationOrientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology
Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Objective: To discuss basic principles of psychopharmacology in children and adolescents. Pharmacokinetics:
More informationTetrachloroethylene: Integrated Risk Information System (IRIS) Draft Toxicological Review Kate Z. Guyton, PhD DABT
Tetrachloroethylene: Integrated Risk Information System (IRIS) Draft Toxicological Review Kate Z. Guyton, PhD DABT National Academy of Sciences Tetrachloroethylene Peer Review Panel November 13, 2008 NCEA
More informationDILI: Clinical Pharmacology Considerations for Risk Assessment
DILI: Clinical Pharmacology Considerations for Risk Assessment Raj Madabushi, PhD Office of Clinical Pharmacology Drug-Induced Liver Injury (DILI) Conference XVII June 06, 2017 Disclaimer: The views expressed
More informationPrinciples of Toxicology: The Study of Poisons
Principles of Toxicology: The Study of Poisons Elizabeth Casarez Department of Pharmacology and Toxicology University it of Arizona The study of the adverse effects of a toxicant on living organisms Adverse
More informationPaediatric Clinical Chemistry
Paediatric Clinical Chemistry Dr N Oosthuizen Dept Chemical Pathology UP 2011 Paediatric biochemistry The child is not a miniature adult Physiological development Immature organ systems Growing individual
More informationDEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA
METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral
More informationObjectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
More informationPharmacotherapy Issues in the Pediatric Population
Pharmacotherapy Issues in the Pediatric Population Continuing Professional Pharmacy Development Dr. Shane Pawluk, PharmD Dr. Andrea Cartwright, PharmD Dr. Maryam Khaja March 26, 2014 Outline Didactic Session
More informationAn In Vitro Alternative For Predicting Systemic Toxicity. By: James McKim, Ph.D., DABT Chief Science Officer
An In Vitro Alternative For Predicting Systemic Toxicity By: James McKim, Ph.D., DABT Chief Science Officer What is Systemic Toxicity and What do We Want From Alternative Methods? Toxicity that occurs
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationUnit 2b: EXCRETION OF DRUGS. Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK)
Unit 2b: EXCRETION OF DRUGS By Ms.M.Gayathri Mpharm (PhD) Department of Pharmaceutics Krishna Teja Pharmacy college Subject code: 15R00603 (BPPK) Excretion, along with metabolism and tissue redistribution,
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationPharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen
Pharmacokinetics in the critically ill Intensive Care Training Program Radboud University Medical Centre Nijmegen In general... Critically ill patients are at higher risk for ADE s and more severe ADE
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More information2. List routes of exposure in the order of most rapid response.
Practice Test questions: 1. What are the two areas of toxicology that a regulatory toxicologist must integrate in order to determine the "safety" of any chemical? 2. List routes of exposure in the order
More informationMODULE No.26: Drug Metabolism
SUBJECT Paper No. and Title Module No. and Title Module Tag PAPER No. 9: Drugs of Abuse MODULE No. 26: Drug Metabolism FSC_P9_M26 TABLE OF CONTENTS 1. Learning Outcomes 2. Introduction 3. Sites of Drug
More informationCysteine Peptide Scientific Review, Dr. S. Dudek, DMV International
Cysteine Peptide Scientific Review, Dr. S. Dudek, DMV International Ethanol and Glutathione Reduced glutathione plays a critical role in cellular detoxification processes including the metabolism of peroxides,
More informationPRODUCT INFORMATION Panadeine EXTRA
PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch
More informationGenetics and Genomics: Influence on Individualization of Medication Regimes
Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics
More informationExposure Dose Health Effects
Exposure Dose Health Effects Understanding the links Elaine Symanski, PhD Mary Ann Smith, PhD The starting basis* How are pollutant levels detected and measured in the human body? If there is some level
More informationMetabolic Changes of Drugs and Related Organic Compounds
Metabolic Changes of Drugs and Related Organic Compounds 3 rd stage/ 1 st course Lecture 7 Shokhan J. Hamid 1 Phase II or Conjugation Reactions Phase I or functionalization reactions do not always produce
More informationStatus of Activities on BPA
Committed since 2002 to ensuring that Europe s food is safe Status of Activities on BPA at International Level Anna F. Castoldi FIP Unit Meeting with National Experts Parma, 29-30 October 2012 International
More informationTissue Dose Based Risk Assessments
Tissue Dose Based Risk Assessments Melvin Andersen The Hamner Institutes for Health Sciences Workshop on Health Risk Assessment of Essential Metals May 6-7, 2008 Ottawa, CA Outline PBPK modeling and the
More informationMetabolism Paracetamol is metabolised in the liver and excreted in the urine mainly as glucuronide and sulphate conjugates.
FEBRAMOL Composition Febramol 150 Suppositories Each suppository contains Paracetamol 150 mg. Suppositories, Tablets & Syrup Febramol 300 Suppositories Each suppository contains Paracetamol 300 mg. Each
More informationDrug Safety Pharmacosurveillance: The Future is Now & Spelled G-e-n-o-m-I-c-s
Drug Safety Pharmacosurveillance: The Future is Now & Spelled G-e-n-o-m-I-c-s Dr. Bruce Carleton University of British Columbia Children s and Women s Health Centre of BC Child & Family Research Institute,
More informationMechanistic Toxicology
SECOND EDITION Mechanistic Toxicology The Molecular Basis of How Chemicals Disrupt Biological Targets URS A. BOELSTERLI CRC Press Tavlor & France Croup CRC Press is an imp^t o* :H Taylor H Francn C'r,,jpi
More informationLecture 5: Principles of Drug Administration Drug Therapy in Special Populations Objectives
Lecture 5: Principles of Drug Administration Drug Therapy in Special Populations Objectives Upon completion of this lecture, student will be able to 1. Describe the roles and responsibilities of nurses
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationMuhammad Fawad Rasool Feras Khalil Stephanie Läer
Clin Pharmacokinet (2015) 54:943 962 DOI 10.1007/s40262-015-0253-7 ORIGINAL RESEARCH ARTICLE A Physiologically Based Pharmacokinetic Drug Disease Model to Predict Carvedilol Exposure in Adult and Paediatric
More informationThe liver in poisoning: what can we learn from animal models?
The liver in poisoning: what can we learn from animal models? Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital 4031 Basel/Switzerland Kraehenbuehl@uhbs.ch Outcome and causes of
More informationPharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist
Pharmacokinetics of strong opioids Susan Addie Specialist palliative care pharmacist What is the difference between pharmacokinetics and pharmacodynamics? Definitions Pharmacokinetics = what the body does
More informationPassage of paracetamol into breast milk and its subsequent metabolism by the neonate
Br. J. clin. Pharmac. (1987), 24, 63-67 Passage of paracetamol into breast milk and its subsequent metabolism by the neonate L. J. NOTARIANNI1, H. G. OLDHAM2 & P. N. BNNTT' 'School of Pharmacy and Pharmacology,
More informationPharmacologic Considerations when using DAAs in Cirrhosis
Pharmacologic Considerations when using DAAs in Cirrhosis Jennifer J. Kiser, PharmD Assistant Professor University of Colorado Denver 1 st International Workshop on the Optimal Use of DAAs in Liver Transplant
More informationEnvironmental Risk Assessment Toxicity Assessment
Environmental Risk Assessment Toxicity Assessment UT Evening School Course Spring Semester 2000 Class #07 on February 29, 2000 Environmental Engineering EV595 Martin Clauberg, Ph.D. 1 Outline of discussion
More information5.3 AZINPHOS METHYL (002)
5.3 AZINPHOS METHYL (002) TOXICOLOGY Azinphos-methyl is the ISO approved common name for S-3,4-dihydro-4-oxo-1,2,3-benzotriazin-3- ylmethyl O,O-dimethyl phosphorodithioate (IUPAC) or O,O-dimethyl S-[(4-oxo-1,2,3-benzotriazin-
More informationSusceptible Populations Workshop January 20-21, 2010 Greenbelt, MD
Susceptible Populations Workshop January 20-21, 2010 Greenbelt, MD CHEMICAL HAZARDS SUSCEPTIBLE POPULATIONS DISCUSSION Participants: Frederick Angulo, Kerry Dearfield, Michael DiNovi, Diana Doell, Michael
More informationSaião A, Chan B, Isbister GK Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, NSW Emergency Department, Prince of Wales
Saião A, Chan B, Isbister GK Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, NSW Emergency Department, Prince of Wales Hospital, Sydney, NSW, Australia Paracetamol Poisoning
More informationAbiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).
For the use only of an Oncologist or a Hospital or a Laboratory ABIRATERONE ACETATE TABLETS Zabiteron-250 COMPOSITION Abiraterone Acetate Tablets 250mg Each uncoated tablets contains: Abiraterone Acetate
More informationExposure (To Stressors) Autism Spectrum Disorders
Exposure (To Stressors) Autism Spectrum Disorders Larry L. Needham, Ph.D. Chief, Organic Analytical Toxicology Branch National Center for Environmental Health Centers for Disease Control and Prevention
More informationPharmacokinetics in pediatric population
Pharmacokinetics in pediatric population Children cannot be considered to be small adults. The physiologic processes that determine drug disposition undergo radical changes during biological maturation.
More informationHelping the liver to detoxify mycotoxins
Helping the liver to detoxify mycotoxins Mycotoxin strategies have so far focused on binding compounds or detoxifying the compounds by feed additives. Animals however, can also detoxify mycotoxins themselves
More informationUpdate on PBTK model-based derivation of HBM-1 values for ethylene glycol monoethyl ether (acetate)
Prof. Wilhelm Huisinga Computational Physiology Group Universität Potsdam Update on PBTK model-based derivation of HBM-1 values for ethylene glycol monoethyl ether (acetate) 49th Sitzung der HBM-Kommission
More information3-MCPD and glycidol and their esters
Toxicological Risk Assessment of 3-monochloropropane-1,2-diol (3-MCPD) Esters and Glycidol Esters: Is there a Need for Concern? Ivonne M.C.M. Rietjens Division of Toxicology Wageningen University ivonne.rietjens@wur.nl
More informationEVE 491/591 Toxicology. Toxicant Distribution 2/20/2014
EVE 491/591 Toxicology Lecture #8 1. Distribution, Storage, Elimination, and Biotransformation of Toxicants 2. Case study #2 Part II Toxicant Distribution Distribution: the process in which a chemical
More informationHTPK: Conducting PK modeling and
HTPK: Conducting PK modeling and simulations at high speed November 5, 2018 Robert Fraczkiewicz, David Miller, Marvin Waldman, Robert D. Clark Slide 1 Session Description and Objectives HTPK lightens the
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationPharmacokinetics: The Basics
Pharmacokinetics: The Basics 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD January 2017 MRC2.CORP.D.00200 1 advice or professional diagnosis. Users seeking medical advice
More informationIntroduction to Pharmacokinetics
- 1 - Introduction to Pharmacokinetics Outline accompanies required webcast for Marie Biancuzzo s Lactation Exam Review and Marie Biancuzzo s Comprehensive Lactation Course Notes We will not cover this
More informationAPPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP
Helsinki, 2 September 20 RAC/26/20/07 Rev. (Agreed at RAC-26) APPLICATION FOR AUTHORISATION: ESTABLISHING REFERENCE DNELS FOR BBP Background At the 22 nd meeting of the Committee for Risk Assessment (RAC)
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationTOXICOKINETICS; DISPOSITION OF XENOBIOTICS (Absorption, Distribution and Excretion of xenobiotics)
TOXICOKINETICS; DISPOSITION OF XENOBIOTICS (Absorption, Distribution and Excretion of xenobiotics) Benay Can Eke, Ph.D., ERT Professor of Toxicology Department of Toxicology Faculty of Pharmacy Ankara
More informationRegulatory Toxicology and Pharmacology
Regulatory Toxicology and Pharmacology 51 (2008) S68 S77 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Biomonitoring Equivalents
More informationDefinition of bilirubin Bilirubin metabolism
Definition of bilirubin Bilirubin metabolism obilirubin formation otransport of bilirubin in plasma ohepatic bilirubin transport oexcretion through intestine Other substances conjugated by glucuronyl transferase.
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Paracetamol 80mg Suppositories 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 80mg Paracetamol For a full list of
More informationBiomarkers of acrylamide
Biomarkers of acrylamide Jan Alexander Department of Food Safety and Nutrition EFSA Colloquium on Acrylamide, Tabiano, Italy, 22-23 May 2008 Scheme of biomarkers Exposure Internal concentration Internal
More informationConcepts in Toxicology Food Toxicology Instructor: Gregory Möller, Ph.D. University of Idaho
Concepts in Toxicology Food Toxicology Instructor: Gregory Möller, Ph.D. University of Idaho Learning Objectives Define toxicology and toxicity. Discuss different types of toxic responses. Explain how
More informationThe Importance of ADME/PK to Inform Human Safety Assessments Based on Animal Studies: Example with Furan. Gregory L. Kedderis, PhD Chapel Hill, NC
The Importance of ADME/PK to Inform Human Safety Assessments Based on Animal Studies: Example with Furan Gregory L. Kedderis, PhD Chapel Hill, NC Conflict of Interest None This research was conducted at
More informationICRP Perspective on Internal Dosimetry OIR and Radiopharmaceuticals
ICRP Perspective on Internal Dosimetry OIR and Radiopharmaceuticals Dietmar Noßke dnosske@web.de 1 Disclaimer The information and views set out in this presentation are those of the author and do not necessarily
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationFORENSIC SCIENCE NEWSLETTER Forensic Pathology and Neuropathology. William A. Cox, M.D., FCAP.
FORENSIC PATHOLOGY FORENSIC SCIENCE NEWSLETTER Forensic Pathology and Neuropathology William A. Cox, M.D., FCAP www.forensicjournals.com June 1, 2016 The Safety of Newborn Infants who are Breast Fed by
More informationNOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES S3A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT
More informationClinical evaluation Jaundice skin and mucous membranes
JAUNDICE Framework The definition of Neonatal Jaundice Billirubin Metabolism Special characteristic in neonates Dangerous of the Hyperbillirubinemia The diseases in relation with Neonatal Jaundice Objectives:
More informationDANIEL R. DOERGE U.S. Food and Drug Administration National Center for Toxicological Research Jefferson, AR
NCTR Research Plan for BPA: Integrating pharmacokinetics in rodent and primate species, rat toxicology studies, human biomonitoring, and PBPK modeling to assess potential human risks from dietary intake
More informationOP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4
Opioid MCQ OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4 OP02 [Mar96] Which factor does NOT predispose to bradycardia with
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More information